Diego Casas Deza, Ana Belén Julián Gomara, Eva Caudevilla Biota, Belén Beltrán, Eugeni Domènech, Ana Gutiérrez Casbas, Miriam Mañosa, Yamile Zabana, Lourdes Roc Alfaro, Emilio Valverde Romero, Elena García González, Beatriz Sicilia, Viviana Laredo, María José Alcalá Escriche, Lucia Madero Velázquez, Rocío Ferreiro Iglesias, Antonia Palmero Pérez, Margalida Calafat, Saioa Rubio Iturria, Irene Moraleja Yudego, Yolanda Ber Nieto, Sandra García Mateo, Javier P Gisbert, Raquel Vicente Lidón, Lara Arias, Erika Alfambra, Pilar Corsino Roche, Manuel Barreiro de Acosta, Santiago García López
OBJECTIVE: the recommendations of the Spanish Ministry of Health on vaccination in risk groups include mesalazine among the treatments with a possible negative effect on its effectiveness. However, this is not the recommendation of most experts. Our objective was to evaluate the effect of mesalazine on the humoral response to the SARS-CoV-2 vaccine in patients with inflammatory bowel disease (IBD). METHODS: VACOVEII is a Spanish, prospective, multicenter study promoted by GETECCU, which evaluates the effectiveness of the SARS-CoV-2 vaccine in patients with IBD...
January 12, 2024: Gastroenterología y Hepatología